Acadia Pharmaceuticals Stock
Acadia Pharmaceuticals Stock
There is an upward development for Acadia Pharmaceuticals compared to yesterday, with an increase of €0.22 (1.450%).
With 22 Buy predictions and 1 Sell predictions Acadia Pharmaceuticals is one of the favorites of our community.
Based on the current price of 15.62 € the target price of 32 € shows a potential of 104.93% for Acadia Pharmaceuticals which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Acadia Pharmaceuticals stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "EBIT growth" there were negative voices in the community.
Pros and Cons of Acadia Pharmaceuticals in the next few years
Pros
?
C******** o* t** e**********
?
M***** P*******
?
B****
Cons
?
S********** s********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Acadia Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Acadia Pharmaceuticals | 1.450% | -1.731% | -7.604% | -19.510% | -45.018% | -8.764% | -33.849% |
| Novocure Ltd | 1.610% | 4.053% | -18.355% | -80.257% | -17.268% | -93.030% | - |
| Sage Therapeutics Inc. | 2.860% | 2.037% | -26.580% | -70.428% | -36.125% | -80.292% | - |
| Iovance Biotherapeutics Inc. | 3.910% | 2.211% | -20.519% | 112.456% | 39.152% | -58.641% | - |
Comments
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $37.00 price target on the stock.
Show more
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $32.00 price target on the stock.
Show more
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target lowered by analysts at JPMorgan Chase & Co. from $29.00 to $25.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for ACAD provided by MarketBeat